Gestodene and EE Patch

Product Overview

Alternative Name: FC-Patch low, Lisvy®

Development Status: SRA/WHO PQ Approved

Target: Female

Mode: Hormonal

Delivery Type: Transdermal

Duration Type: Short-acting

Description: One patch applied once per week for three weeks (21 days) followed by one week without patch per cycle. Each patch contains 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene.

Updated date: May 30, 2018

Vertical Tabs

Status

Project Phase: Post-development

Project Stage: Regulatory

Status Details:
  • This patch was approved in the EU in 2014 and has been outlicensed by Bayer to Gedeon Richter, a Hungarian Pharma company. Market entry is planned for late 2015, with the name of Lisvy®.

Download Product Report